(Q37837903)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

CSF biomarkers in neurodegenerative diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Niklas Mattsson

series ordinal

1

1 reference

24 August 2017

publication date

9 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

Clinical Chemistry and Laboratory Medicine

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

345-352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Plasma Abeta in Alzheimer's disease--up or down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Safety and acceptability of the research lumbar puncture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Biological fluid biomarkers in neurodegenerative parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Alzheimer's disease: strategies for disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Increased levels of GFAP in the cerebrospinal fluid in three subtypes of genetically confirmed Alexander disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

F2-isoprostanes in Alzheimer and other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF biomarkers: pinpointing Alzheimer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

The mucopolysaccharidoses: a success of molecular medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Biomarkers and surrogate markers: an FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

The uses of biomarkers in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

The use of PET in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.082

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.082

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21303297%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference